Anthem Biosciences Share Price Surges 27% on NSE Debut: Buy, Sell, or Hold?

Let’s break it down together in a simple, conversational way — because, let’s face it, biotech stocks can be tricky if you’re not neck-deep in market jargon.

What Happened With Anthem Biosciences IPO Listing?

Anthem Biosciences, a biotech company making big waves in the pharma and CRDMO (Contract Research, Development & Manufacturing Organization) space, launched its Rs 3,395-crore IPO in mid-July 2025. Priced between Rs 540 to Rs 570, the IPO was a massive hit — subscribed nearly 64 times.

On July 21, it made its debut on both the NSE and BSE, with Anthem Biosciences share price listing at Rs 723.05 on NSE and Rs 723.10 on BSE. That’s a premium of nearly 27% over its upper band issue price.

Not bad, right?

Grey Market Premium (GMP) vs Reality

Before listing, Anthem Biosciences IPO GMP (Grey Market Premium) was floating around 31%, so the actual listing was slightly below those grey market expectations. Still, a 27% jump isn’t anything to scoff at — especially in a volatile biotech market.

Market Cap and Anchor Investment Support

Post-listing, Anthem’s market capitalization hit a whopping Rs 40,610.02 crore. This valuation was further supported by Rs 1,016 crore raised from anchor investors ahead of the IPO, signaling strong institutional trust in Anthem’s business model.

What Makes Anthem Biosciences Stand Out?

So, why is everyone so hyped about Anthem Biosciences share price?

Well, according to Naren Agarwal, CEO of Wealth1, Anthem is not just another biotech company. It’s India’s most comprehensive CRDMO platform. What does that mean in plain English?

Imagine a one-stop biotech shop that handles everything from research to manufacturing for big pharma. Anthem specializes in:

• Fermentation APIs

• Peptides

• Oligonucleotides

• Antibody Drug Conjugates (ADCs)

• RNA Therapeutics

They also boast India’s largest fermentation capacity at 182 kL and cater to 675+ clients across 44 countries.

Basically, they’re not playing small — they’re global.

Strong Financial Backbone

The numbers tell a convincing story too:

• Revenue CAGR: 25–30%

• EBITDA Margins: Nearly 37%

• ROCE (Return on Capital Employed): High teens

Those are some sweet metrics for a newly listed company. And because the IPO was a pure Offer For Sale (OFS), there’s no dilution pressure. Anthem starts its public journey with a clean cap table, which is a big green flag for investors.

Valuation Perspective: Expensive or Justified?

According to Narendra Solanki from Anand Rathi Shares, Anthem Biosciences IPO valuation is based on an annualized FY25 PE of 70.6x. That might seem steep to some, but in the high-growth biotech space, that’s not uncommon.

He believes the issue is fairly priced, considering the:

• Robust growth pipeline

• Industry-leading margins

• Consistent profitability

His advice? Hold for the long term if you got shares during the IPO. The runway for growth is solid.

Anthem’s Position in India’s Biotech Boom

India’s biotech sector is heating up fast. With government incentives and a growing global demand for cost-effective R&D outsourcing, companies like Anthem are poised to ride the next biotech wave.

Think of Anthem as a biotech backbone for Big Pharma—offering services across the entire drug lifecycle, especially for both small molecules and biologics.

Not many Indian companies can say the same.

Should You Buy, Sell, or Hold Anthem Biosciences Shares?

Let’s weigh your options:

✅ Buy If:

• You missed the IPO but believe in long-term biotech growth.

• You’re impressed with Anthem’s global client base and margins.

• You’re okay with short-term volatility in exchange for long-term upside.

🤔 Hold If:

• You got allotment in the IPO and are sitting on early gains.

• You’re waiting for the Q2 earnings before making a move.

• You want to see how the broader market reacts over the next quarter.

❌ Sell If:

• You’re a short-term investor and want to lock in 25–27% gains.

• You think the stock is overvalued at a PE of 70x.

• You’re worried about overall biotech market fluctuations.

What to Watch Next?

Here’s what could move the Anthem Biosciences share price in the coming weeks:

• Q2 Earnings Report – A strong quarter could boost investor confidence.

• Management Commentary – Strategic plans, global expansions, or new partnerships could be big.

• Industry Updates – Any major news in CRDMO or biotech regulations could impact sentiment.

• GMP Movement – Still relevant for future momentum, especially in short-term trading.

Anthem Biosciences Share Price Target 2025: Any Guesses?

While analysts haven’t officially posted detailed Anthem Biosciences share price target for 2025, early trends suggest the company could comfortably trade between Rs 850–950, assuming consistent earnings growth and macro tailwinds.

But hey, this is biotech. It could shoot past that range if they announce a killer deal or acquisition.

Final Thoughts: Is Anthem the Flagship Stock for India’s Biotech Rise?

Anthem Biosciences isn’t just another listing. It represents a turning point in India’s pharmaceutical landscape. With global clients, robust financials, and a massive capacity advantage, Anthem could become the Infosys of Biotech — the one stock that leads an entire sector into the spotlight.

But remember, every stock has its risks. Don’t invest just because it’s hot. Do your homework, check your goals, and listen to your gut.

Conclusion

In a market filled with hype and noise, Anthem Biosciences share price listing at a 27% premium is not just a headline — it’s a statement. Backed by solid numbers and a vision for global pharma leadership, Anthem is a stock worth watching, especially if you’re into long-term plays in high-growth sectors.

So, whether you’re buying, holding, or just observing, Anthem Biosciences has officially entered the big leagues. Don’t be surprised if it becomes one of the defining stocks of this decade in India’s biotech boom.